Overview
Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance
Status:
Completed
Completed
Trial end date:
2011-12-01
2011-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a Phase 2 study designed to assess the ability of RP-G28 to improve lactose digestion and tolerance.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Ritter Pharmaceuticals, Inc.
Criteria
Inclusion Criteria:- Male and female subjects. Female subjects must be non-pregnant and non-lactating.
- 18 to 64 years of age inclusive at Screening
- Current or recent history of intolerance to milk and other dairy products
- Acceptable Baseline Lactose Intolerance Symptom Scores
- Acceptable Result on Baseline Hydrogen Breath Test
- Subjects must agree to refrain from all other treatments and products used for lactose
intolerance during the study
Exclusion Criteria:
- Disorders known to be associated with abnormal GI motility
- History of surgery that alters the normal function of the gastrointestinal tract
- Past or present; organ transplant, chronic pancreatitis, pancreatic insufficiency,
symptomatic biliary disease, Celiac disease, inflammatory bowel disease (IBD),
ulcerative colitis, Crohn's disease, irritable bowel syndrome (IBS)
- Active gastric or duodenal ulcers or history of severe ulcers
- Diabetes mellitus (type 1 or type 2)
- Congestive Heart Failure
- History of Human Immunodeficiency Virus (HIV), Hepatitis B or C
- Use of concurrent therapy(ies) for symptoms of lactose intolerance
- Uncontrolled BP defined as sitting systolic blood pressure (SBP) ≥160 mmHg or
diastolic blood pressure (DBP) ≥95 mmHg at Visit 1
- History of ethanol abuse in the past 12 months
- History of drug abuse within 12 months
- History or presence of malignancy within the past 5 years (except basal cell or
squamous cell carcinoma removed from a sun-exposed area)
- Use of any investigational drug or participation in any investigational study within
30 days prior to Screening